Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

638.88 -3.71 (-0.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
62 63 Next >
News headline image
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗
 
Via Benzinga
News headline image
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
News headline image
Bull Market Buys: 2 Growth Stocks to Own for the Long Run ↗
These companies are no strangers to beating the market. 
Via The Motley Fool
News headline image
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand ↗
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast. 
Via Benzinga
News headline image
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients ↗
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
Via Benzinga
News headline image
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today ↗
 
Via Benzinga
News headline image
Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst ↗
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth. 
Via Benzinga
News headline image
3 Standout Stocks to Buy for the Next Bull Market ↗
These standout stocks to buy for a bull market offer promising potential for significant gains as market conditions continue to strengthen. 
Via InvestorPlace
News headline image
Stocks to Buy: 7 Founder-Led Companies Set to Outperform ↗
These founder-led companies are at the forefront of industry innovation, and historical trends indicate that they will likely outperform. 
Via InvestorPlace
News headline image
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today ↗
 
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling ↗
 
Via Benzinga
News headline image
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗
Revenue is climbing at these two drug companies -- and the trend should continue. 
Via The Motley Fool
News headline image
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
News headline image
Healthcare Stocks Continue To Lag The Market-Can Anything Help ? ↗
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
News headline image
3 No-Brainer Stocks to Buy in July ↗
Investors shouldn't have to think too hard about these great stocks. 
Via The Motley Fool
News headline image
3 Pharma Stocks Already Ushering in the Next Biotech Boom ↗
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider. 
Via InvestorPlace
News headline image
The 3 Best Biotech Stocks to Buy in July 2024 ↗
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024. 
Via InvestorPlace
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
7 High Priced Stocks That Would Benefit From a Stock Split ↗
These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names. 
Via InvestorPlace
News headline image
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data ↗
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What's Going On With Regeneron Pharmaceuticals Stock On Friday? ↗
Regeneron Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval of odronextamab. Final decision... 
Via Benzinga
News headline image
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product ↗
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.